DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+8.61%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.13B
AUM Growth
-$216M
(-6.5%)
Cap. Flow
-$396M
Cap. Flow
% of AUM
-12.65%
Top 10 Holdings %
Top 10 Hldgs %
41.39%
Holding
77
New
10
Increased
20
Reduced
24
Closed
8
Top Buys
| 1 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$78.4M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$54.8M |
| 3 |
Immunovant
IMVT
|
$41.7M |
| 4 |
Guardant Health
GH
|
$34.4M |
| 5 |
Kura Oncology
KURA
|
$30.8M |
Top Sells
| 1 |
Amgen
AMGN
|
$180M |
| 2 |
Insmed
INSM
|
$134M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$122M |
| 4 |
Travere Therapeutics
TVTX
|
$95.7M |
| 5 |
Axsome Therapeutics
AXSM
|
$89.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Context Therapeutics
CNTX
$75.6M
| $14.5M | 0.46% |
7,419,355
| – | – |
|
|
CYBN
52
Cybin
CYBN
$142M
| $13.6M | 0.43% |
1,529,987
-1
| -0% | -$9 |
|
53
Zura Bio
ZURA
$132M
| $13.3M | 0.42% |
3,283,783
| – | – |
|
54
Invivyd
IVVD
$218M
| $11.2M | 0.35% |
10,953,937
| – | – |
|
|
CLYM
55
Climb Bio, Inc. Common Stock
CLYM
$151M
| $11M | 0.35% |
2,169,143
-1,735,642
| -44% | -$8.83M |
|
56
Inovio Pharmaceuticals
INO
$144M
| $10.4M | 0.33% |
1,804,366
-262,354
| -13% | -$1.52M |
|
57
Avalo Therapeutics
AVTX
$139M
| $9.19M | 0.29% |
+967,000
| New | +$9.19M |
|
58
Neumora Therapeutics
NMRA
$283M
| $7.5M | 0.24% |
+567,428
| New | +$7.5M |
|
|
59
Travere Therapeutics
TVTX
$1.75B
| $7.44M | 0.24% |
531,857
-6,838,143
| -93% | -$95.7M |
|
|
VIGL
60
DELISTED
Vigil Neuroscience
VIGL
| $5.28M | 0.17% |
1,553,996
+956,781
| +160% | +$3.25M |
|
|
RGLS
61
DELISTED
Regulus Therapeutics
RGLS
| $5.12M | 0.16% |
3,262,564
| – | – |
|
|
ALLK
62
DELISTED
Allakos
ALLK
| $3.27M | 0.1% |
5,000,000
| – | – |
|
63
Alto Neuroscience
ANRO
$97.7M
| $2.51M | 0.08% |
219,648
-292,038
| -57% | -$3.34M |
|
64
Prothena Corp
PRTA
$452M
| $2.34M | 0.07% |
+140,000
| New | +$2.34M |
|
65
Relmada Therapeutics
RLMD
$48.8M
| $2.19M | 0.07% |
674,833
-559,940
| -45% | -$1.81M |
|
66
Aligos Therapeutics
ALGS
$75.1M
| $2.11M | 0.07% |
244,110
-1
| -0% | -$9 |
|
|
SYRS
67
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $1.78M | 0.06% |
828,485
| – | – |
|
68
Metagenomi
MGX
$67.2M
| $667K | 0.02% |
307,500
-158,732
| -34% | -$344K |
|
69
Scholar Rock
SRRK
$3.3B
| $385K | 0.01% |
48,100
-324,459
| -87% | -$2.6M |
|
|
AGEN
70
Agenus
AGEN
$136M
| – | – |
-313,359
| Closed | -$5.25M |
|
|
71
Alnylam Pharmaceuticals
ALNY
$58.6B
| – | – |
-500,000
| Closed | -$122M |
|
|
72
Amgen
AMGN
$153B
| – | – |
-575,000
| Closed | -$180M |
|
73
Cogent Biosciences
COGT
$1.83B
| – | – |
-308,235
| Closed | -$2.6M |
|
74
HilleVax
HLVX
$105M
| – | – |
-1,832,652
| Closed | -$26.5M |
|
|
75
Insmed
INSM
$30.3B
| – | – |
-2,000,000
| Closed | -$134M |
|